Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2003 Target Snapshot

Retinoic acid receptor gamma · SINGLE PROTEIN · Homo sapiens

724Compounds
229Assays
17Approved Drugs
701.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-12

Retinoic acid receptor gamma shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P13631. Start with acne, then reuse UniProt P13631 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acne, then reuse UniProt P13631 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-12 1 linked drug
Open source guide
Disease program
acne

Retinoic acid receptor gamma shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with acne because it currently carries approved-linked support. Linked drugs include TRIFAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Retinoic acid receptor gamma as ChEMBL target CHEMBL2003, mapped to UniProt P13631. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Retinoic acid receptor gamma
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
ChEMBL target ID
CHEMBL2003
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
P13631
Retinoic acid receptor gamma
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Retinoic acid receptor gamma is the right protein anchor across sources, using UniProt P13631 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acne is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRetinoic acid receptor gamma
UniProt AccessionP13631
Component TypeProtein
Sequence Length454 aa

Retinoic acid receptor gamma

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Retinoic acid receptor gamma, mapped to UniProt P13631. Sequence length is 454 aa.

Mapped IDP13631
Review nameRetinoic acid receptor gamma
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Retinoic acid receptor gamma shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
acne
1 linked drug · 1 direct · 1 efficacy
Linked drugTRIFAROTENE
Approved-linked Approved
fibrodysplasia ossificans progressiva
1 linked drug · 1 direct · 1 efficacy
Linked drugPALOVAROTENE
Clinical signal Phase II
lamellar ichthyosis
1 linked drug · 1 direct · 1 efficacy
Linked drugTRIFAROTENE
Clinical signal Phase I
dry eye syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugPALOVAROTENE
Clinical signal Phase I
lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugTRIFAROTENE
Clinical signal Phase I
Ossification, Heterotopic
1 linked drug · 1 direct · 1 efficacy
Linked drugPALOVAROTENE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with acne because it currently carries approved-linked support. Linked drugs include TRIFAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacne
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

17
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC50117.0
KI138.0
EC50296.0
KD150.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL38 10.4 Ki 0.04 Approved
CHEMBL5997757 10.19 EC50 0.065 Preclinical
CHEMBL3939687 9.92 Kd 0.12 Preclinical
CHEMBL38 9.7 EC50 0.2 Approved
CHEMBL38 9.7 Kd 0.2 Approved
CHEMBL4210595 9.66 EC50 0.22 Preclinical
CHEMBL3907274 9.6 Kd 0.25 Preclinical
CHEMBL3936922 9.6 Kd 0.25 Preclinical
CHEMBL3945228 9.6 Kd 0.25 Preclinical
CHEMBL89241 9.47 EC50 0.34 Preclinical
Distribution

pChEMBL Value Distribution

46
5.0
29
5.5
45
6.0
61
6.5
69
7.0
81
7.5
54
8.0
32
8.5
25
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRIFAROTENE
CHEMBL3707313
Approved 2019
TAMIBAROTENE
CHEMBL25202
Approved 2005
ALITRETINOIN
CHEMBL705
Approved 1999
BEXAROTENE
CHEMBL1023
Approved 1999
TAZAROTENE
CHEMBL1657
Approved 1997
ADAPALENE
CHEMBL1265
Approved 1996
TRETINOIN
CHEMBL38
Approved 1971
Assay Landscape

Assay Landscape

229
Total Assays
306
Tested Compounds
3
Assay Types
Binding — 157 assays, 306 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 91 152 7.2
cell-based format 65 153 7.3
assay format 1 1 6.0
Functional — 71 assays, 44 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 45 21 7.0
assay format 26 23 7.9
ADME — 1 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 3 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine